



**Department of Vermont Health Access  
Pharmacy Benefits Management Program  
*DUR Board Meeting Agenda***

---

**January 10, 2012 6:30 – 9:00 p.m.**

- 1. Executive Session** **6:30 - 7:00**
  - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))
  
- 2. Introductions and Approval of DUR Board Minutes** **7:00 - 7:05**  
(Public Comment Prior to Board Action)
  
- 3. DVHA Pharmacy Administration Updates** **7:05 - 7:25**
  - Single Formulary
  - Specialty Pharmacy
  - Program Integrity Overview
  
- 4. Medical Director Update** **7:25 - 7:30**
  - Clinical Programs Update
  - Prescriber Comments
  
- 5. Follow-up Items from Previous Meetings** **7:30 - 7:40**
  - Latuda<sup>®</sup>
  
- 6. RetroDUR** **7:40 - 7:50**
  - Seroquel<sup>®</sup> Low Dose Initiative
  
- 7. Clinical Update: Drug Reviews** **7:50 – 8:05**  
(Public comment prior to Board action)
  - Abbreviated Drug Reviews**
    - Horizant<sup>®</sup> (gabapentin enacarbil) ER Tablet
    - Phoslyra<sup>®</sup> (calcium acetate) Oral Solution
  
  - Full New Drug Reviews**
    - Xarelto<sup>®</sup> (rivaroxaban) Tablet
  
- 8. Therapeutic Drug Classes – Periodic Review** **8:05 – 8:40**  
(Public comment prior to Board action)  
**Class review documents available on DVHA web site 1/10/2012 @ 12 Noon**
  - Anti-Diabetics
    - DPP-4 Inhibitors
    - Peptide Hormones: Amylinomimetics (Symlin<sup>®</sup>)
    - Peptide Hormones: Incretin Mimetics
  - Growth Hormone

- Multiple Sclerosis Medications
  - MS Biologic Response Modifiers
  - Potassium Channel Blockers (Ampyra<sup>®</sup>)
- Ophthalmics
  - Antibiotics
  - Antihistamines
  - NSAIDs
- Vaginal
  - Antibiotics
  - Antifungals (recommend not to manage aside from OTC management)

**9. New Managed Therapeutic Drug Classes** **8:40 – 8:40**  
 (Public comment prior to Board action)

- None

**10. Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products** **8:40 – 8:45**  
 (Public comment prior to Board action)

- Atypical Antipsychotics: Long Acting Injectable Products

**11. General Announcements** **8:45– 8:55**

**Selected FDA Safety Alerts**

- Gilenya<sup>®</sup> (fingolimod): Drug Safety Communication - Safety Review of a Reported Death After the First Dose
- Multaq<sup>®</sup> (dronedarone): Drug Safety Communication - Increased Risk of Death or Serious Cardiovascular Events
- Pradaxa<sup>®</sup> (dabigatran etexilate mesylate): Drug Safety Communication - Safety Review of Post-Market Reports of Serious Bleeding Events
- Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants: Drug Safety Communication - Use During Pregnancy and Potential Risk of Persistent Pulmonary Hypertension of the Newborn
- Zocor<sup>®</sup> (simvastatin): Label Change - New Restrictions, Contraindications, and Dose Limitations

**Other**

- ALTITUDE Study of Aliskiren Terminated Early by Novartis

**12. Adjourn** **9:00**